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Background: The process of malignant transformation, progression and metastasis of melanoma is not completely
understood. Recently, the microarray technology has been used to survey transcriptional differences that might
provide insight into the metastatic process, but the validation of changing gene expression during metastatic
transition period is poorly investigated. A large body of literature has been produced on the role of the HOX genes
network in tumour evolution, suggesting the involvement of HOX genes in several types of human cancers.
Deregulated paralogous group 13 HOX genes expression has been detected in melanoma, cervical cancer and
odonthogenic tumors. Among these, Hox C13 is also involved in the expression control of the human keratin genes
hHa5 and hHa2, and recently it was identified as a member of human DNA replication complexes.
Methods: In this study, to investigate HOX C13 expression in melanoma progression, we have compared its
expression pattern between naevi, primary melanoma and metastasis. In addition HOXC13 profile pattern of
expression has been evaluated in melanoma cell lines.
Results: Our results show the strong and progressive HOX C13 overexpression in metastatic melanoma tissues and
cytological samples compared to nevi and primary melanoma tissues and cells.
Conclusions: The data presentated in the paper suggest a possible role of HOX C13 in metastatic melanoma switch.
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Melanoma is the most frequent skin malignancy, with
poor prognosis because associated to high metastatic
capacity [1]. Currently, although several molecular path-
ways have been described for melanoma progression, the
molecular mechanisms that lead to metastasis develop-
ment have not completely understood [1]. HOX genes
regulate normal embryonic development, cell differenti-
ation and other critical processes in eukaryotic cell life.
Several studies have shown that HOX genes play a role
in regulating the homeostasis and both proliferation and
differentiation of skin cells during development [2-4].
Moreover, recently, it has been better investigated their
role in neoplastic transformation in several human tis-
sues [5-10]. In particular the genes belonging to HOX* Correspondence: monicantile@libero.it
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reproduction in any medium, provided the orparalogous group 13 seem to have a relevant role in both
neoplasia development and progression. Thus HOX B13
gene deregulation is strongly associated to breast and
ovarian carcinogenesis [11-14] and its expression appears
cytoplasmic during epidermis embryonic development,
and nuclear in differentiated adult epidermal cells, while
in epidermal proliferative disorders cytoplasmic expression
has been documented [15]. Moreover, we have identified a
significant prognostic role of HOX D13 in pancreatic can-
cer [16] and recently, it was shown that HOX A13 plays a
relevant role in human hepatocarcinoma progression [17].
Finally, the amplification of 12q13-15, containing HOX
C13 gene and the entire HOX C locus, was associated with
a large number of cancers such as sarcomas, glioblast-
omas, lung, bladder and transitional carcinomas and mela-
nomas [18-25].
In skin homeostatsis HOX C13 plays a fundamental
role, particularly in epithelial component, being mainly
involved in the control of nails, hair and hair folliclesLtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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cytokeratins genes tying a highly conserved motif in the
promoter of these genes [26-28].
In this study, to investigate HOX C13 role in melanoma
progression, we have compared its expression pattern be-
tween juctional, compound and dermic naevi and primary
and metastatic human melanoma. Moreover we have eval-
uated HOXC13 expression in melanoma cell lines. In par-
ticular we have built a melanoma progression Tissue
Micro Array (TMA) in order to perform immunohisto-
chemistry analysis of HOX C13 expression. Moreover we
have analyzed through quantitative Real Time PCR (qRT-
PCR) analysis HOX C13 mRNA expression in the same
series of samples and in melanoma cell lines.Methods
Patients
Histological blocks of cases have been selected in the files
of Pathology Unit of National Cancer Institute Fondazione
G. Pascale of Naples and all patients were caucasians, and
all gave their written informed consent according to the
institutional regulations.
This study was approved by the ethics committee of
National Cancer Institute “G. Pascale”. Our series included
nevi, primary melanomas and corresponding metastatic
tissues from the same patients and an independent series
of cytologic nodal melanoma metastases. All histological
tissue cases were reviewed by three pathologists (AA, RF,
GB) according to AJCC classification criteria, using stand-
ard tissue sections and appropriate immunohistochemical
slides. Moreover medical records have been reviewed for
clinical information. Synthethically clinicopathologic para-
meters re-evaluated in our study for each tumor included
patient age at initial diagnosis; tumor size; histologic sub-
type; sentinel lymphnode status; non sentinel lymphnode
metastasis; number of positive lymph nodes; tumor stage;
tumor recurrence or distant metastasis; type of surgery.Cell lines
The human MEL-Juso lines was cultured in RPMI 1640
medium supplemented with 5.1 ml of L-glutamine and
10% fetal calf serum; WM115 was kept in half Emem
supplemented with 2 mM L-glutamine, 1% nonessential
amino acids, 1% sodium pyruvate (NaP) and 10% fetal
calf serum; SK-MEL, A-375, MZ2, Me-15 and Me-51,
and Me-67 were grown in DMEM Ham’s F12 supple-
mented with 2 mM L-glutamine and 10% fetal calf
serum; The HBL-8 and NA-8 were cultured in RPMI
1640 supplemented with 1 mM NaP, 2 mM non-
essential amino acids, 2 mM L-glutamine and 10% fetal
calf serum. The cells were maintained in an incubator at
37°C in a humidified atmosphere with 5% CO2.TMA building
Tissue Micro-Array was built using the most representa-
tive areas from each single case of metastasis. All
tumours and controls were reviewed by three experi-
enced pathologists (AA,RF,GB). Discrepancies between
two pathologists from the same case were resolved in a
joint analysis of the cases. Tissue cylinders with a diam-
eter of 0.6 mm were punched from morphologically rep-
resentative tissue areas of each ‘donor’ tissue block and
brought into one recipient paraffin block (3 × 2.5 cm)
using a semiautomated tissue arrayer (Galileo TMA).
HOX C13 Immunostaining
Human hair follicles histological sample were used as
positive control. Immunohistochemical and immuno-
cytochemical staining was done on slides from formalin-
fixed, paraffin embedded tissues, and cytological samples
on thin prep to evaluate the expression of HOX C13
marker. Paraffin slides were then deparaffinized in xy-
lene and rehydrated through graded alchols. Antigen re-
trieval was performed by microwave pretreatment in
0.01M citrate buffer for 10 min. After protein block
(BSA 5% in PBS 1x), the slides were incubated with pri-
mary antibody to human HOX C13 (dilution 1:1200,
cod.ab55251, Abcam,Cambridge,UK) over night. Sec-
tions were incubated with mouse anti-rabbit or goat
anti-mouse secondary IgG biotinylated secondary anti-
body for 30 min. Immunoreactivity was visualised by
means of avidin–biotin–peroxydase complex kit reagents
(Novocastra, Newcastle, UK) as the chromogenic sub-
strate. Finally, sections were weakly counterstained with
haematoxylin and mounted. Human hair follicles were
used as positive controls. Irrelevant rabbit or mouse IgG
antibodies were applied to negative control. Standard
sections for primitive melanoma and melanoma metasta-
sis TMA have been used. Results are interpreted using a
light microscope.
Double staining IHC
For double staining of HMB-45 and HOX C13, deparaf-
finized sections were microwaved in 1 mmol/L EDTA
(pH 8.0) for two cycles of 5 minutes each to unmask epi-
topes. After treatment with 1% hydrogen peroxidase for
30 minutes to block endogenous peroxide, the sections
were subsequently incubated with HOXC13 monoclonal
antibody over night at 7°C. Followed by a wash step to
remove any excess antibody. The antibody was visualized
using the peroxidase detection system consists of EnVi-
sion™ FLEX+, Mouse (LINKER) (Dako, SM804) and after
wash step EnVision™ FLEX/HRP (Dako, SM802) both
for 30 minutes a room temperature. Finally, was used
the diaminobenzidine (DAB) as contrasting chromogen.
Antibody denaturation (DNS001H, 1 part A with 3
part B, Biocare Medical, USA) was then performed for
Table 1 Clinicopathological characteristics of melanoma patients and tumors and relation with HOXC13 expression
HOX C13 Score 0 1 2 3 Sample N°
Sex N°
Male 1 (4,5%) 13 (59,1%) 7 (31,8%) 1 (4,5%) 48 0,945
Female 2 (7,7%) 16 (61,5%) 8 (30,8%) 0 (0%)
Clark level
I 0 (0%) 2 (100,0%) 0 (0%) 0 (0%)
II 0 (0%) 10 (62,5%) 6 (37,5%) 0 (0%) 48 0,1111
III 3 (12,0%) 13 (52,0%) 9 (36,0%) 0 (0%)
IV 0 (0%) 4 (80,0%) 0 (0%) 1 (20,0%)
Pt
I 0 (0%) 6 (100,0%) 0% 0%
II 0 (0%) 6 (37,5%) 9 (56,3%) 1 (6,3%) 48 0,0001
III 3 (42,9%) 2 (28,6%) 2 (28,6%) 0 (0%)
IV 0 (0%) 15 (78,9%) 4 (21,1%) 0 (0%)
Mitotic rate per mm2
0 0 (0%) 9 (75,0%) 2 (16,7%) 1 (8,3%)
>1 3 (10,0%) 16 (53,3%) 11(36,7%) 0 (0%) 42 0,133
TILs
Absent 1 (5,9%) 10 (58,8%) 5 (29,4%) 1 (5,9%)
Nonbrisk 0 (0%) 13 (61,9%) 8 (38,1%) 0 (0%) 48 0,339
Brisk 2 (20,0%) 6 (60,0%) 2 (20,0%) 0 (0%)
Ulceration
Present 1 (5,9%) 11 (64,7%) 5 (29,4%) 0 (0%) 48 1
Absent 2 (6,5%) 18 (58,1%) 10(32,3%) 1 (3,2%)
Predominant cell type
Epithelioid 1 (3,2%) 22 (71,0%) 8 (25,8%) 0 (0%)
Spindle 2 (20,0%) 2 (20,0%) 5 (50,0%) 1 (10,0%) 48 0,045
Other 0 (0%) 5 (71,4%) 2 (28,6%) 0 (0%)
Melanoma Type
Superficial spreading melanoma 0 (0%) 7 (77,8%) 2 (22,2%) 0 (0%)
Nodular melanoma 3 (12,5%) 12 (50,0%) 9 (37,5%) 0 (0%) 48 0,286
Acrolentiginous melanoma 0 (0%) 6 (75,0%) 1 (12,5%) 1 (12,5%)
Lentigo maligna melanoma 0 (0%) 4 (57,1%) 3 (42,9%) 0 (0%)
Sentinel lymph node
negative 3 (11,1%) 16 (59,3%) 7 (25,9%) 1 (3,7%)
micrometastases 0 (0%) 4 (80,0%) 1 (20,0%) 0 (0%) 48 0,431
subcapsular 0 (0%) 7 (77,8%) 2 (22,2%) 0 (0%)
diffuse 0 (0%) 2 (28,6%) 5 (71,4%) 0 (0%)
Nevus 8(80,0%) 2(20,0%) 0(0%) 0(0%) 10
Primary melanoma 3(6,3%) 29(60,4%) 15(31,3%) 1(2,1%) 48
Metastasis
1 2 (33,3%) 2 (33,3%) 2 (33,3%) 0 (0%)
2 0 (0%) 10 (83,3%) 1 (8,3%) 1 (8,3%) 48 0,013
3 1 (3,3%) 17 (56,7%) 12(40,0%) 0 (0%)
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Table 2 Clinical characteristics of cytological melanoma
samples and relation with HOXC13 expression
HOX C13 Score 0 1 2 3 Sample N°
Sex N°
Male 1 (9,1%) 1 (9,1%) 5 (45,5%) 4 (36,4%) 20
Female 0 (0%) 2 (22,2%) 2 (22,2%) 5 (55,6%)
Age
<60 0 (0%) 2 (22,2%) 3 (33,3%) 4 (44,4%) 20
>60 1 (9,1%) 1 (9,1%) 4 (36,4%) 5 (45,5%)
pT
I 0 (0%) 0 (0%) 1(100%) 0(0%) 20
II 0 (0%) 0 (0%) 0 (0%) 5 (100%)
III 1 (14,3%) 1 (14,3%) 3 (42,9%) 2 (28,6%)
IV 0 (0%) 2 (28,6%) 3 (42,9%) 2 (28,6%)
Lymph node localization
axillary 1 (11,1%) 0 (0%) 4 (44,4%) 4 (44,4%) 20
inguinal 0 (0%) 2 (28,6%) 2 (28,6%) 3 (42,9%)
iliac region 0 (0%) 1 (100%) 0 (0%) 0 (0%)
scapulary 0 (0%) 0 (0%) 0 (0%) 1 (100%)
supraclavicular 0 (0%) 0 (0%) 1 (50%) 1 (50%)
Figure 1 Localization of HOX C13 protein in human hair follicles:
immunopositivity (red) in cortex (co), in cuticle (cu), in hair papilla
(hp), and in germinative cells (gc). Immunonegativity in medulla
(me), in outer root sheath (ors), in connective sheath (cs) and inner root
sheath (irs).
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pletely inactivated before applying the second primary
antibody. Thus, HMB45 monoclonal antibody (pre-
diluited, cod. 790–4366, Ventana Medical System, Tuc-
son, USA) was subsequently applied as a second primary
antibody and was incubated for 45 min. HMB45 was
visualized using the MACH 2 mouse Ap-polymer
(MALP521H, Biocare Medical, USA) for 30 min and
incubated with Vulcan fast red for 15 min (FR805H, Bio-
care Medical, USA).
Evaluation of immunohistochemistry
For HOX C13 expression on the positive control, we
considered nuclear positivity. For HOX C13 on melan-
oma tissues, cytoplasmatic and nuclear staining have
been considered. Melanoma tissues were scored semi-
quantitatively by evaluating the proportion of positive
tumour cells over the total number of tumour cells (per-
centage of positive tumour cells per tissue microarray
punch). Negative (Score 0), low expression cases, and,
high expression cases were recorded when neoplastic
cells expressing HOX C13 were between 0 and 10%
(Score 1+), lower than 30% (score 2+) and higher than
30% (Score 3+), respectively. For the evaluation of HOX
C13 expression in cytologic specimens, we considered
the percentage of positive cells by the same score used
for assessment of histological samples. For the evalu-
ation of IHC double staining, we considered nuclear
HOX C13 (brown) expression and cytoplasmatic HMB-
45 (red) expression.
RNA extraction from fresh cellular sospension and
paraffin embedded tissues
The sections obtained from paraffin-embedded samples
were incubated at 37°C in the presence of xylene for
about 20 minutes. Total RNA was purified using High
Pure FFPE RNA Micro Kit (Roche) following the manu-
facturer’s instructions. Total RNA was isolated from
cytological samples and cell lines sospensions, using
RNeasy Mini Kit (Qiagen GmbH, Hilden, Germany) fol-
lowing the manufacturer’s instructions. All samples were
treated with RNase-free DNase (Qiagen GmbH, Hilden,
Germany) to prevent amplification of genomic DNA. A
total of 1 μg RNA was subjected to cDNA synthesis for
1 hr at 37°C using the Ready To Go You-Primer First-
Strand Beads kit (Amersham Biosciences Europe Gmbh,
Freiburg, Germany, cod. 27-9264-01) in a reactionmix-
ture containing 0.5 μg random hexamers (GeneAmp
RNA PCR Random Hexamers Set N808-0127 Applied
Biosystems, Foster City, CA).
Real-time PCR
qRT-PCR was performed in a LightCycler system (Roche
Molecular Biochemicals, Mannheim, Germany) using
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glass capillaries with The LightCycler TaqMan Master Mix
(cod. 04735536001, Roche Molecular Biochemicals), 10 μl,
in a volume of 20 μl containing 2 μl of cDNA and 1 μl of
specific TaqMan Gene Expression Assays for human HOX
C13 (RealTime Designer Assay cod. 04162498001, Roche
Molecular Biochemicals), according to the manufacturer’s
directions. All reactions were performed in triplicate. The
thermal cycling conditions included a step of 20 sec at 95° C
followed by a 40 cycles of 95° C for 1 sec and 60°C for
20 sec. The comparative Ct method was employed to
determine the human HOX C13 gene variation, using as
reference gene TaqMan Endogenous Controls Human
ACTB (β-actin) Endogenous Control (RealTime Designer
Assay cod.05532957001, Roche Molecular Biochemicals).
We identified a calibrator cell line that represents the uni-
tary amount of the target of interest, consequently the sam-
ples express n-fold mRNA relative to the calibrator. Final
amounts of target were determined as follows:
target amount=2-Ct, where Ct= [Ct (HOXC13)−Ct
(ACTB)]sample− [Ct (HOXC13)−Ct (ACTB)]calibrator.Statistical analysis
The association between HOX C13 with other clinico-
pathological parameters was conducted using the κ 2 and
T Student test. The Pearson κ 2 test was used to deter-
mine whether a relationship exists between the variablesFigure 2 HOX C13 immunostaining in melanoma tissues. A: HOX C13
C13 immunonegativity in primary melanoma sample (40X); C: High HOX C
High HOX C13 immunopositivity in melanoma micro-metastasis sample scoincluded in the study. The level of significance
was defined as P< 0.05. Overall Survival (OS) and
Progression-Free Survival (PFS) curves were calculated
using the Kaplan-Meier method. Statistical significance of
associations between individual variables and OS and FFS
was determined using the log-rank test. All the statistical
analyses were carried out using the Statistical Package for
Social Science 8.0 software (SPSS Inc., Chicago, IL, USA).
OS was defined as the time from diagnosis (first biopsy) to
death by any cause or until the most recent follow-up.
PFS was measured as the time from diagnosis to the oc-
currence of progression, relapse after complete remission,
or death from any cause.Results
Clinicopathological characteristics of melanoma patients
and tumors
Our series of histological samples have been constituted
by 48 primary melanoma and corresponding metastases,
and 10 nevi (Table 1). Female patients represented from
26 out of 48 (54.2%); Clark level was I in 4% (2/48), II in
33% (16/48) III in 52% (25/48) and IV in 10% (5/48) of
cases; Pt was I in 12% (6/48), II in 33% (16/48), III in
14% (7/48), IV in 39% (19/48) of cases; Mitotic rate was
0 in 28% (12/42) and >1 in 71% (30/42) of cases; TILs
was absent in 35% (17/48), Non-brisk in 43% (21/48)
and Brisk in 20% (10/48) of cases; ulceration was presentimmunopositivity in hair bulb follicle as positive control (20X); B: HOX
13 immunopositivity in melanoma metastasis sample score 3+ (20X); D:
re 3+ (60X).
Figure 3 HOX C13 immunostaining in limphnode melanoma
cytological samples. A: HOX C13 immunopositivity score 1+ (60X);
B: HOX C13 immunopositivity score 2+ (60X); C: HOX C13
immunopositivity score 3+ (60X).
Cantile et al. Journal of Translational Medicine 2012, 10:91 Page 6 of 10
http://www.translational-medicine.com/content/10/1/91in 35% (17/48) and absent in 64% (31/48) of cases; Cell
Type predominant was epithelioid cells (64%) and Nodu-
lar melanoma type was prevalent (50%).
In addition, 20 cytological lymph node metastases of
melanoma samples were selected for our study and clin-
ical characteristics of patients with respect to HOX C13
expression are shown in Table 2.
Expression of HOXC13 protein in primary and metastatic
melanoma tissues and cytological samples
For HOX C13 expression on the positive control, we
detected nuclear positivity (red) in cortex, cuticle, dermal
papilla and germinative cell compartment of hair follicle
(Figure 1). In all dermic naevus the expression was absent,
while it was low/moderate (5/15%) in most primary melan-
oma samples. Moreover, in primary melanomas the expres-
sion of HOX C13 was negative in three cases (6.3%), in 29
cases score 1 positivity (60.4%), in 15 cases (31.5%) scores
2 positivity and score 3 (2.1%) in one case have been
observed. Cytoplasmic positivity gnerally has been
observed with focal nuclear expression. In corresponding
metastatic tissues specimens, in 29 cases HOX C13 expres-
sion appears with score 3 (60.4%), in 11 cases (22.9%) with
score 2, and only in 6 cases with score 1. In metastatic cells
a significant higher nuclear positivity has been observed
(Figure 2, Table 1). Table 3 presents data on the expression
of HOX C13 in metastases of different bodily localization,
where it is shown the predominant expression (score 3+)
in lymph node metastases (73.3%). Furthermore, HOX C13
expression was very high (score 3+) in most cytological
samples of nodal melanoma metastasis and with prevalent
cytoplasmatic localization (80%) (Figure 3, Table 3). In
addition, we developed a double staining with melanoma-
specific marker HMB-45 in primary and metastatic melan-
oma samples (Figures 4 and 5) and found that all HOX
C13-positive tumour cells also expressed HMB-45.
HOXC13 mRNA quantification in histological and
cytological melanoma samples and in primary and
metastatic cell lines
HOX C13 gene expression was evaluated on selected pri-
mary and metastatic melanoma tissues by qRT-PCR. In
nevous samples HOX C13 mRNA expression appears si-
lent, except in one case (Figure 6). In primary samples it
was observed a low expression in samples 7 and 8, whileTable 3 Relation between HOX C13 expression and
metastases localization
HOX C13 Score 0 1 2 3 Sample N°
Lymph node met. 0 (0%) 2 (13,3%) 2 (13,3%) 11(73,3%) 15
Skin met. 1 (8,3%) 0 (0%) 4 (33,3%) 7 (58,3%) 12
Visceral met. 1 (4,8%) 4 (19,0%) 5 (23,8%) 11(52,4%) 21
48it was moderate in remainder melanoma tissues analyzed
(between five and ten-fold increase). In all correspond-
ing metastatic melanoma samples it was observed a sig-
nificant increase in HOX C13 mRNA expression
(between ten and hundred-fold increase) (Figure 6).
Gene expression analysis was also performed on the
same cytological samples used for immunostaining, and
Figure 4 HOX C13/HMB-45 double staining IHC in primary melanoma tissues. A: HOX C13 immunonegativity in HMB-45 positive (red)
primary melanoma (10X); B: details of melanoma cells in papillary dermis (20X); C: details of melanoma cells in reticular dermis (20x).
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tween ten and hundred-fold increase) (Figure 7). RT-
PCR quantification was also performed on selected com-
mercially primary and metastatic melanoma cell lines. In
WM-115 and JUSO primary melanoma cultures HOX
C13 mRNA expression appears moderate (between three
and ten-fold increase), while in all metastatic cell lines it
was observed a significant increase of gene expression
(between ten and hundred-fold increase) (Figure 8).Statistical analysis
χ square analysis has shown a significant association be-
tween absent/low HOXC13 expression and pT1-2 stageFigure 5 HOX C13/HMB-45 double staining IHC in metastatic melanoma
C13 immunopositivity (brown) in nodal metastasis (20X); B: Cytoplasm HMB-4
in nodal subcapsular micrometastasis (40X) C: Cytoplasm HMB-45 immunopos
metastasis (40X).group of patients (p= 0.0001) and epithelioid phenotype
(p= 0.045) (Table 1). HOX C13 expression in metastasis
were significant higher in metatasis with respect to
primitive melanomas (p= 0.013) (Table 1). In cytological
samples has shown a prevalent score 3+ HOX C13 ex-
pression, independently of the clinical characteristics of
patients (Table 2). Survival analysis of melanona cases
included in TMA related to the HOX C13 expression
did not reveal statistically significant results.Discussion
Metastasis development is the prognostic key of melan-
oma progression, but the molecular mechanisms thattissues. A: Cytoplasm HMB-45 immunopositivity (red) and nuclear HOX
5 immunopositivity (red) and nuclear HOX C13 immunopositivity (brown)
itivity (red) and nuclear HOX C13 immunopositivity (brown) in dermal
Figure 6 HOX C13 Real Time expression in primary and metastatic melanoma tissues. All reactions were performed in triplicate and data are
expressed as mean of relative amount of mRNAs levels.
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the primary tumors, conquer the bloodstream, and invade
new tissues are still poorly known. The entire network of
HOX genes plays a crucial role in embryonic develop-
ment, and is involved in controlling of cell identity pheno-
type and three-dimensional organs and tissues formation
[28-34]. Alterations of specific groups of HOX genes can
be associated with neoplastic transformation of different
tissues and organs, such as breast, kidney, colon, lung, thy-
roid, bladder, prostate, lymphoid organ and skin tissue [6].
Thus the possibility of identifing the levels of expression
of these genes may be important for diagnosis and prog-
nosis of these pathologies. HOX genes belonging to par-
alogous group 13 are able to generate mutations not
compatible with life, as in the case of synpolydactyly [35],
and hand-foot-genital syndrome [36]. In addition they areFigure 7 HOX C13 Real Time expression in cytological melanoma sam
as mean of relative amount of mRNAs levels.directly associated with the processes of cell proliferation
and differentiation in vivo and vitro and cancer progres-
sion [11,37]. In this study we investigated the role played
by HOX C13, located a chromosomal area, 12q13-15,
widely studied in human tumorigenesis.
Our results show the strong and progressive over-
expression of HOX C13 in melanoma metastatis when
compared to nevi and primary melanomas, suggesting
the HOX C13 role in metastatic melanoma switch.
These results have een confirmed in melanoma metasta-
sis cell lines. There are few indications in the literature
regarding the role of HOX genes network in melanoma
development and in the progression of this neoplasia.
The first work carried out in vitro on metastatic melan-
oma cell lines showed the aberrant expression of a block
of genes located at 5 end of the HOX C locus (HOX C10,ples. All reactions were performed in triplicate and data are expressed
Figure 8 HOX C13 Real Time expression in primary and metastatic cell lines. All reactions were performed in triplicate and data are
expressed as mean of relative amount of mRNAs levels.
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sive properties (integrins and ICAM-I), to a Gln-Arg mu-
tation in the codon 61 of the N-RAS gene, and to the
expression of IL-1a, IL-6, and TNF-alpha [38]. After,
Maeda et al. .have been shown the alteration of specific
HOX genes in melanoma genesis and metastasis [39].
Furthermore, more recently a gene expression profiling
of primary, non-metastatic cutaneous tumors and meta-
static melanoma has resulted in the identification of several
genes that may be centrally involved in the progression
and metastatic potential of melanoma identyfing several
HOX genes as fundamental in this process [40]. To con-
duct our analysis we selected a range of human biological
samples representative of malignant melanoma progres-
sion. The data obtained showed that HOX C13 expression,
is significantly increased in metastatis analyzed compared
to the corresponding primary tumors of the same patients.
Our data conflicted with previously published data [39]
that showed higher expression of HOXC13 in nevi and pT1/
pT2 as compared to pT4 and decreased expression in more
advanced tumors. However, in the paper of Maeda et al.
were not used metastatic samples and corresponding pri-
mary tumors from the same patients, representing progres-
sion of the disease. Moreover, all our data have been
produced for immunohistochemistry and confirmed by
qRT-PCR, and this has allowed us to verify that alterations
in HOX C13 expression are maintened both gene and pro-
tein level. In fact, often the correspondence between the two
expression profiles are not comparable.Conclusions
The search for new molecular markers that allow to se-
lect the tumor cell clones with respect to their aggres-
siveness and their ability to metastasize, is certainly one
of the most important goals in melanoma biomedical re-
search, and in this context, the HOX genes represent
ideal targets for such studies. In fact, HOX C13 could be
an ideal marker on which to interfere at both mRNA
and protein level.We speculate that our data may represent an important
element for the development of potential therapies tar-
geted against the activities of HOX C13. In fact, recently, it
was shown that several molecules, as antisense oligo-
nucleotide (ASO) and small interfering RNA (siRNA),
could be able to interact with crucial genes in the modify-
ing tumoral cells growth and proliferation and thus repre-
senting ideal tools for targeted therapy [41].
Moreover, Pre-B-Cell-Leukemia transcription factors (PBX),
a family of genes belonging to the TALE superfamily of
homeobox genes, [42,43] are able to interact with a subset of
HOX proteins, influencing the regulation of transcription and
are required for many aspect of the Hox function. The possi-
bility of targeting the post-translational interaction between
HOX proteins and their PBX cofactors, through the short
peptide HXR9 that is able to bind a conserved six-amino acid
sequence in the HOX proteins, to block in vivo and vitro the
HOX/PBX-regulated gene expression of melanoma cells has
been shown recently [44].
In conclusion, targeting HOX/PBX interaction may
represents a potential alternative or addition to current
cancer therapies when drug resistance develops also in
therapies against melanoma progression.
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